{"id": "article-20197_0", "title": "Cyclobenzaprine -- Continuing Education Activity", "content": "Cyclobenzaprine is FDA-approved as an adjunct to rest for the treatment of muscle spasms associated with acute, painful musculoskeletal conditions. Cyclobenzaprine is a part of a group of medications referred to as cyclical antidepressants. Cyclobenzaprine is a tricyclic amine salt that works in the central nervous system (CNS) as a depressant that reduces muscle hyperactivity. These cyclical antidepressants have roles in treating depression, neuropathic pain, migraine prophylaxis, attention deficit hyperactive disorder, and potential muscle relaxation properties. In addition, this activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of cyclobenzaprine for members of the interprofessional team who will potentially prescribe or encounter patients taking cyclobenzaprine.", "contents": "Cyclobenzaprine -- Continuing Education Activity. Cyclobenzaprine is FDA-approved as an adjunct to rest for the treatment of muscle spasms associated with acute, painful musculoskeletal conditions. Cyclobenzaprine is a part of a group of medications referred to as cyclical antidepressants. Cyclobenzaprine is a tricyclic amine salt that works in the central nervous system (CNS) as a depressant that reduces muscle hyperactivity. These cyclical antidepressants have roles in treating depression, neuropathic pain, migraine prophylaxis, attention deficit hyperactive disorder, and potential muscle relaxation properties. In addition, this activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of cyclobenzaprine for members of the interprofessional team who will potentially prescribe or encounter patients taking cyclobenzaprine."}
{"id": "article-20197_1", "title": "Cyclobenzaprine -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of cyclobenzaprine. Review the FDA-approved indications for cyclobenzaprine. Outline the important potential adverse events with cyclobenzaprine. Review the importance of improving care coordination among interprofessional team members to improve outcomes for patients for whom cyclobenzaprine is a therapeutic option. Access free multiple choice questions on this topic.", "contents": "Cyclobenzaprine -- Continuing Education Activity. Objectives: Identify the mechanism of action of cyclobenzaprine. Review the FDA-approved indications for cyclobenzaprine. Outline the important potential adverse events with cyclobenzaprine. Review the importance of improving care coordination among interprofessional team members to improve outcomes for patients for whom cyclobenzaprine is a therapeutic option. Access free multiple choice questions on this topic."}
{"id": "article-20197_2", "title": "Cyclobenzaprine -- Indications", "content": "Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants. Cyclobenzaprine is a tricyclic amine salt that works in the central nervous system (CNS) as a depressant that reduces muscle hyperactivity. Clinical indications for cyclobenzaprine are described below.", "contents": "Cyclobenzaprine -- Indications. Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants. Cyclobenzaprine is a tricyclic amine salt that works in the central nervous system (CNS) as a depressant that reduces muscle hyperactivity. Clinical indications for cyclobenzaprine are described below."}
{"id": "article-20197_3", "title": "Cyclobenzaprine -- Indications -- FDA-approved Indication", "content": "Cyclobenzaprine is approved as an adjunct to rest and physical therapy to relieve muscle spasms associated with acute, painful musculoskeletal conditions for short-term use.\u00a0Cyclobenzaprine should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available, and muscle spasms due to\u00a0acute, painful musculoskeletal conditions are generally short-duration. Specific therapy for longer periods is seldom warranted. [1]", "contents": "Cyclobenzaprine -- Indications -- FDA-approved Indication. Cyclobenzaprine is approved as an adjunct to rest and physical therapy to relieve muscle spasms associated with acute, painful musculoskeletal conditions for short-term use.\u00a0Cyclobenzaprine should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available, and muscle spasms due to\u00a0acute, painful musculoskeletal conditions are generally short-duration. Specific therapy for longer periods is seldom warranted. [1]"}
{"id": "article-20197_4", "title": "Cyclobenzaprine -- Indications -- Off-label Clinical Uses", "content": "Fibromyalgia: American College of Rheumatology guidelines advise duloxetine, milnacipran, and pregabalin as the first line therapy,\u00a0but cyclobenzaprine may be useful for associated insomnia. [2] [3] [4] Myofascial pain due to temporomandibular disorders [5] A recent randomized controlled trial indicates that sublingual cyclobenzaprine decreases posttraumatic stress disorder(PTSD) symptoms and improves sleep and psychosocial function. However, this is preliminary evidence, and extensive research is still needed. [6]", "contents": "Cyclobenzaprine -- Indications -- Off-label Clinical Uses. Fibromyalgia: American College of Rheumatology guidelines advise duloxetine, milnacipran, and pregabalin as the first line therapy,\u00a0but cyclobenzaprine may be useful for associated insomnia. [2] [3] [4] Myofascial pain due to temporomandibular disorders [5] A recent randomized controlled trial indicates that sublingual cyclobenzaprine decreases posttraumatic stress disorder(PTSD) symptoms and improves sleep and psychosocial function. However, this is preliminary evidence, and extensive research is still needed. [6]"}
{"id": "article-20197_5", "title": "Cyclobenzaprine -- Mechanism of Action", "content": "Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepr [7] essants. Cyclobenzaprine relieves skeletal muscle spasms of local origin without interfering with muscle function. In preclinical research, cyclobenzaprine reduced skeletal muscle hyperactivity. Research indicates that it primarily acts within the central nervous system in the brain stem.", "contents": "Cyclobenzaprine -- Mechanism of Action. Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepr [7] essants. Cyclobenzaprine relieves skeletal muscle spasms of local origin without interfering with muscle function. In preclinical research, cyclobenzaprine reduced skeletal muscle hyperactivity. Research indicates that it primarily acts within the central nervous system in the brain stem."}
{"id": "article-20197_6", "title": "Cyclobenzaprine -- Mechanism of Action", "content": "Cyclobenzaprine does not work directly on skeletal muscle or the neuromuscular junction, although an overlapping action on the spinal cord may contribute to its overall skeletal muscle relaxant activity. Evidence implies that the\u00a0resultant\u00a0impact of cyclobenzaprine is a decline of tonic somatic motor activity, affecting both gamma(\u03b3) and alpha(\u03b1) motor systems. Recent\u00a0research suggests that cyclobenzaprine is a (5-HT2) receptor antagonist, and this additional action is responsible for\u00a0its\u00a0antispasmodic\u00a0effect. [8]", "contents": "Cyclobenzaprine -- Mechanism of Action. Cyclobenzaprine does not work directly on skeletal muscle or the neuromuscular junction, although an overlapping action on the spinal cord may contribute to its overall skeletal muscle relaxant activity. Evidence implies that the\u00a0resultant\u00a0impact of cyclobenzaprine is a decline of tonic somatic motor activity, affecting both gamma(\u03b3) and alpha(\u03b1) motor systems. Recent\u00a0research suggests that cyclobenzaprine is a (5-HT2) receptor antagonist, and this additional action is responsible for\u00a0its\u00a0antispasmodic\u00a0effect. [8]"}
{"id": "article-20197_7", "title": "Cyclobenzaprine -- Mechanism of Action", "content": "Cyclobenzaprine effectively improves muscle spasms, reduces local pain and tenderness, and increases the range of motion in acute, painful musculoskeletal conditions. [1] Cyclobenzaprine is an antispasmodic\u00a0drug effective in treating muscle spasms. However, cyclobenzaprine\u00a0is not an antispasticity drug.\u00a0Therefore, cyclobenzaprine is ineffective\u00a0in treating spasticity associated with cerebral or spinal cord pathology or children with cerebral palsy. [9]", "contents": "Cyclobenzaprine -- Mechanism of Action. Cyclobenzaprine effectively improves muscle spasms, reduces local pain and tenderness, and increases the range of motion in acute, painful musculoskeletal conditions. [1] Cyclobenzaprine is an antispasmodic\u00a0drug effective in treating muscle spasms. However, cyclobenzaprine\u00a0is not an antispasticity drug.\u00a0Therefore, cyclobenzaprine is ineffective\u00a0in treating spasticity associated with cerebral or spinal cord pathology or children with cerebral palsy. [9]"}
{"id": "article-20197_8", "title": "Cyclobenzaprine -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: The time to peak plasma cyclobenzaprine concentration (Tmax) is 7 to 8 hours for cyclobenzaprine extended-release formulation and approximately 4 hours for immediate release formulation. The steady-state plasma concentration is attained within 3 to 4 days. Food increases the extent(AUC) and rate of absorption of cyclobenzaprine. [10] Distribution: Cyclobenzaprine is highly bound to plasma protein(93%) and binds primarily to alpha-1 glycoprotein, an acute phase reactant protein elevated in inflammatory conditions). [7] Metabolism: Cyclobenzaprine is metabolized by cytochrome P450 enzymes (CYP3A4, CYP31A2, and CYP2D6).", "contents": "Cyclobenzaprine -- Mechanism of Action -- Pharmacokinetics. Absorption: The time to peak plasma cyclobenzaprine concentration (Tmax) is 7 to 8 hours for cyclobenzaprine extended-release formulation and approximately 4 hours for immediate release formulation. The steady-state plasma concentration is attained within 3 to 4 days. Food increases the extent(AUC) and rate of absorption of cyclobenzaprine. [10] Distribution: Cyclobenzaprine is highly bound to plasma protein(93%) and binds primarily to alpha-1 glycoprotein, an acute phase reactant protein elevated in inflammatory conditions). [7] Metabolism: Cyclobenzaprine is metabolized by cytochrome P450 enzymes (CYP3A4, CYP31A2, and CYP2D6)."}
{"id": "article-20197_9", "title": "Cyclobenzaprine -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: Cyclobenzaprine follows first-order pharmacokinetics. The mean elimination half-life for the immediate-release formulation is 18 hours(range 8 to 37 hours), and for the extended-release formulation is approximately 32 hours. Cyclobenzaprine is excreted predominantly as glucuronides via the kidney.", "contents": "Cyclobenzaprine -- Mechanism of Action -- Pharmacokinetics. Excretion: Cyclobenzaprine follows first-order pharmacokinetics. The mean elimination half-life for the immediate-release formulation is 18 hours(range 8 to 37 hours), and for the extended-release formulation is approximately 32 hours. Cyclobenzaprine is excreted predominantly as glucuronides via the kidney."}
{"id": "article-20197_10", "title": "Cyclobenzaprine -- Administration", "content": "Cyclobenzaprine administration is via the oral route. It is available in immediate-release tablets\u00a0of 5 milligrams, 7.5 milligrams, and 10 milligrams and extended-release capsules of 15 milligrams and 30 milligrams and is usually given three times daily. The maximum recommended dose per day is 30 milligrams. The extended-release formulation should be administered at the same time each day. The capsule may be swallowed whole, but its contents also may be sprinkled onto a tablespoon of applesauce for immediate consumption without chewing the granules. The patient should rinse their mouth to ensure that they have swallowed all the contents.", "contents": "Cyclobenzaprine -- Administration. Cyclobenzaprine administration is via the oral route. It is available in immediate-release tablets\u00a0of 5 milligrams, 7.5 milligrams, and 10 milligrams and extended-release capsules of 15 milligrams and 30 milligrams and is usually given three times daily. The maximum recommended dose per day is 30 milligrams. The extended-release formulation should be administered at the same time each day. The capsule may be swallowed whole, but its contents also may be sprinkled onto a tablespoon of applesauce for immediate consumption without chewing the granules. The patient should rinse their mouth to ensure that they have swallowed all the contents."}
{"id": "article-20197_11", "title": "Cyclobenzaprine -- Administration -- Use in Specific Patient Populations", "content": "Patients with Hepatic Impairment: Steady-state plasma concentrations are twofold higher in\u00a0patients with mild hepatic insufficiency than in healthy controls. Cyclobenzaprine should be used cautiously in patients with mild hepatic impairment. The usual starting should be a 5 mg dose, and if needed, it can be titrated upwards. Cyclobenzaprine is not recommended in patients with moderate to severe hepatic impairment due to the lack of clinical data and safety concerns. [11]", "contents": "Cyclobenzaprine -- Administration -- Use in Specific Patient Populations. Patients with Hepatic Impairment: Steady-state plasma concentrations are twofold higher in\u00a0patients with mild hepatic insufficiency than in healthy controls. Cyclobenzaprine should be used cautiously in patients with mild hepatic impairment. The usual starting should be a 5 mg dose, and if needed, it can be titrated upwards. Cyclobenzaprine is not recommended in patients with moderate to severe hepatic impairment due to the lack of clinical data and safety concerns. [11]"}
{"id": "article-20197_12", "title": "Cyclobenzaprine -- Administration -- Use in Specific Patient Populations", "content": "Patients with Renal Impairment: No information about dose adjustment has been provided in the manufacturer's product information. However, due to its potent anticholinergic adverse effects, sedation, and increased risk of fractures, use should be avoided in chronic kidney disease, especially in\u00a0elderly patients(American Geriatric society, Beers criteria). [12] [13]", "contents": "Cyclobenzaprine -- Administration -- Use in Specific Patient Populations. Patients with Renal Impairment: No information about dose adjustment has been provided in the manufacturer's product information. However, due to its potent anticholinergic adverse effects, sedation, and increased risk of fractures, use should be avoided in chronic kidney disease, especially in\u00a0elderly patients(American Geriatric society, Beers criteria). [12] [13]"}
{"id": "article-20197_13", "title": "Cyclobenzaprine -- Administration -- Use in Specific Patient Populations", "content": "Pregnancy Considerations: The use of cyclobenzaprine is reported safe in animal reproduction studies. However, there is a lack of clinical data regarding the use of cyclobenzaprine in human pregnancy and its outcomes. Consequently, cyclobenzaprine should be used during pregnancy only if needed.", "contents": "Cyclobenzaprine -- Administration -- Use in Specific Patient Populations. Pregnancy Considerations: The use of cyclobenzaprine is reported safe in animal reproduction studies. However, there is a lack of clinical data regarding the use of cyclobenzaprine in human pregnancy and its outcomes. Consequently, cyclobenzaprine should be used during pregnancy only if needed."}
{"id": "article-20197_14", "title": "Cyclobenzaprine -- Administration -- Use in Specific Patient Populations", "content": "Breastfeeding Considerations: Breastfeeding Considerations:\u00a0Amounts of cyclobenzaprine in milk appear to be extremely low. If cyclobenzaprine is indicated for the mother, breastfeeding can be continued with caution. Monitor the infant for sedation and developmental milestones, especially in neonates, preterm infants, and when using sedating drugs concomitantly. [14]", "contents": "Cyclobenzaprine -- Administration -- Use in Specific Patient Populations. Breastfeeding Considerations: Breastfeeding Considerations:\u00a0Amounts of cyclobenzaprine in milk appear to be extremely low. If cyclobenzaprine is indicated for the mother, breastfeeding can be continued with caution. Monitor the infant for sedation and developmental milestones, especially in neonates, preterm infants, and when using sedating drugs concomitantly. [14]"}
{"id": "article-20197_15", "title": "Cyclobenzaprine -- Adverse Effects", "content": "The most common adverse\u00a0drug reactions of cyclobenzaprine are somnolence, dry mucous membranes, dizziness, and confusion. Like other cyclical antidepressants, cyclobenzaprine antagonizes the muscarinic receptors, which may produce undesired side effects such as xerostomia, ileus, tachycardia, mydriasis, confusion, urinary retention, and hallucinations. Additionally, cyclobenzaprine antagonizes the alpha1 adrenergic receptor, causing a vasodilatory effect, and may contribute further to reflex tachycardia. [15] [16] [17] Chronic cyclobenzaprine use can cause minor\u00a0ALT elevation, but no reports of severe hepatotoxicity are reported. [18]", "contents": "Cyclobenzaprine -- Adverse Effects. The most common adverse\u00a0drug reactions of cyclobenzaprine are somnolence, dry mucous membranes, dizziness, and confusion. Like other cyclical antidepressants, cyclobenzaprine antagonizes the muscarinic receptors, which may produce undesired side effects such as xerostomia, ileus, tachycardia, mydriasis, confusion, urinary retention, and hallucinations. Additionally, cyclobenzaprine antagonizes the alpha1 adrenergic receptor, causing a vasodilatory effect, and may contribute further to reflex tachycardia. [15] [16] [17] Chronic cyclobenzaprine use can cause minor\u00a0ALT elevation, but no reports of severe hepatotoxicity are reported. [18]"}
{"id": "article-20197_16", "title": "Cyclobenzaprine -- Contraindications", "content": "Cyclobenzaprine is contraindicated in prior hypersensitivity reactions and the conditions listed below. [19] [20] Hyperthyroidism Myocardial infarction(the acute recovery phase) Arrhythmias Heart failure Heart block or conduction disturbances 14 days of taking a monoamine oxidase inhibitor(MAOI)", "contents": "Cyclobenzaprine -- Contraindications. Cyclobenzaprine is contraindicated in prior hypersensitivity reactions and the conditions listed below. [19] [20] Hyperthyroidism Myocardial infarction(the acute recovery phase) Arrhythmias Heart failure Heart block or conduction disturbances 14 days of taking a monoamine oxidase inhibitor(MAOI)"}
{"id": "article-20197_17", "title": "Cyclobenzaprine -- Monitoring", "content": "Clinicians should monitor for signs and symptoms of serotonin syndrome if the patient is taking other serotonergic drugs.\u00a0In two case reports, the authors described patients who quickly developed serotonin syndrome after initiating cyclobenzaprine in the short term. In both cases, the patients took serotonergic medications (phenelzine and duloxetine) before starting cyclobenzaprine. [21] Clinicians should also monitor for vital signs, as cyclobenzaprine can cause reflex tachycardia.", "contents": "Cyclobenzaprine -- Monitoring. Clinicians should monitor for signs and symptoms of serotonin syndrome if the patient is taking other serotonergic drugs.\u00a0In two case reports, the authors described patients who quickly developed serotonin syndrome after initiating cyclobenzaprine in the short term. In both cases, the patients took serotonergic medications (phenelzine and duloxetine) before starting cyclobenzaprine. [21] Clinicians should also monitor for vital signs, as cyclobenzaprine can cause reflex tachycardia."}
{"id": "article-20197_18", "title": "Cyclobenzaprine -- Monitoring", "content": "Healthcare providers should use the numerical rating scale (NRS), verbal rating scale (VRS), Visual Analogue Scale (VAS), and Faces Pain Scale-Revised (FPS-R) for the assessment of pain and to monitor the response to cyclobenzaprine therapy. [22] [23] When using cyclobenzaprine for TMJ disorders, monitor the response to therapy with a graded chronic pain scale (GCPS). [24] At each visit, clinicians should evaluate the necessity and monitor the patients for cyclobenzaprine use, as it is frequently overprescribed for a long duration in clinical practice. [25]", "contents": "Cyclobenzaprine -- Monitoring. Healthcare providers should use the numerical rating scale (NRS), verbal rating scale (VRS), Visual Analogue Scale (VAS), and Faces Pain Scale-Revised (FPS-R) for the assessment of pain and to monitor the response to cyclobenzaprine therapy. [22] [23] When using cyclobenzaprine for TMJ disorders, monitor the response to therapy with a graded chronic pain scale (GCPS). [24] At each visit, clinicians should evaluate the necessity and monitor the patients for cyclobenzaprine use, as it is frequently overprescribed for a long duration in clinical practice. [25]"}
{"id": "article-20197_19", "title": "Cyclobenzaprine -- Toxicity", "content": "Cyclobenzaprine is structurally and pharmacologically related to tricyclic antidepressants. Among the most dreaded toxicities linked with cyclical antidepressants, overdoses affect fast-acting sodium channels in the cardiac conduction system. Cyclical antidepressants block the cardiac sodium channel and cause prolongation of cardiac depolarization, which manifests as QRS widening on electrocardiograms. There is also evidence that cyclical antidepressants may decrease the seizure threshold by interfering with chloride conductance on the GABA receptor.", "contents": "Cyclobenzaprine -- Toxicity. Cyclobenzaprine is structurally and pharmacologically related to tricyclic antidepressants. Among the most dreaded toxicities linked with cyclical antidepressants, overdoses affect fast-acting sodium channels in the cardiac conduction system. Cyclical antidepressants block the cardiac sodium channel and cause prolongation of cardiac depolarization, which manifests as QRS widening on electrocardiograms. There is also evidence that cyclical antidepressants may decrease the seizure threshold by interfering with chloride conductance on the GABA receptor."}
{"id": "article-20197_20", "title": "Cyclobenzaprine -- Toxicity", "content": "One study retrospectively looked at 750 charts at five regional poison centers between the years 1989 to 1993. Based on their retrospective study, the authors concluded that cyclobenzaprine in toxic doses less than 1000 mg does not appear to produce the life-threatening neurotoxicity and cardiotoxic dysrhythmias associated with traditional tricyclic antidepressants. The case report of cyclobenzaprine toxicity describes ileus and\u00a0simultaneous ST segment elevations on EKG. [26]", "contents": "Cyclobenzaprine -- Toxicity. One study retrospectively looked at 750 charts at five regional poison centers between the years 1989 to 1993. Based on their retrospective study, the authors concluded that cyclobenzaprine in toxic doses less than 1000 mg does not appear to produce the life-threatening neurotoxicity and cardiotoxic dysrhythmias associated with traditional tricyclic antidepressants. The case report of cyclobenzaprine toxicity describes ileus and\u00a0simultaneous ST segment elevations on EKG. [26]"}
{"id": "article-20197_21", "title": "Cyclobenzaprine -- Toxicity", "content": "Other case reports, however, have implicated cyclobenzaprine in acute overdose as the culprit leading to fatalities. For example, there were two reported cases of overdoses in which elevated levels of cyclobenzaprine were found in postmortem evaluations of the patients. The authors, therefore, document an association linking elevated cyclobenzaprine levels with two examples of presumed fatal overdoses. [27]", "contents": "Cyclobenzaprine -- Toxicity. Other case reports, however, have implicated cyclobenzaprine in acute overdose as the culprit leading to fatalities. For example, there were two reported cases of overdoses in which elevated levels of cyclobenzaprine were found in postmortem evaluations of the patients. The authors, therefore, document an association linking elevated cyclobenzaprine levels with two examples of presumed fatal overdoses. [27]"}
{"id": "article-20197_22", "title": "Cyclobenzaprine -- Toxicity", "content": "The most common effects associated with cyclobenzaprine overdose are drowsiness and tachycardia. Rare but potentially critical manifestations of overdose are cardiac arrest, cardiac dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome. Changes in the electrocardiogram, particularly in the QRS axis or width, are clinically significant indicators of cyclobenzaprine toxicity. [20]", "contents": "Cyclobenzaprine -- Toxicity. The most common effects associated with cyclobenzaprine overdose are drowsiness and tachycardia. Rare but potentially critical manifestations of overdose are cardiac arrest, cardiac dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome. Changes in the electrocardiogram, particularly in the QRS axis or width, are clinically significant indicators of cyclobenzaprine toxicity. [20]"}
{"id": "article-20197_23", "title": "Cyclobenzaprine -- Toxicity", "content": "To summarize, treatment beyond GI decontamination is unnecessary for less than 100 mg ingestions. Cyclobenzaprine does not appear to produce life-threatening cardiovascular or neurologic effects in doses less than 1000 mg,\u00a0and serious toxicity such as arrhythmias, hypotension, and seizures occur at doses greater than 1000 mg. [28]", "contents": "Cyclobenzaprine -- Toxicity. To summarize, treatment beyond GI decontamination is unnecessary for less than 100 mg ingestions. Cyclobenzaprine does not appear to produce life-threatening cardiovascular or neurologic effects in doses less than 1000 mg,\u00a0and serious toxicity such as arrhythmias, hypotension, and seizures occur at doses greater than 1000 mg. [28]"}
{"id": "article-20197_24", "title": "Cyclobenzaprine -- Toxicity", "content": "Although rare, deaths may occur from overdosage(>1000 mg) with cyclobenzaprine. As management of overdose is complex, the\u00a0clinician\u00a0should contact a poison control center for the latest information on treatment.", "contents": "Cyclobenzaprine -- Toxicity. Although rare, deaths may occur from overdosage(>1000 mg) with cyclobenzaprine. As management of overdose is complex, the\u00a0clinician\u00a0should contact a poison control center for the latest information on treatment."}
{"id": "article-20197_25", "title": "Cyclobenzaprine -- Toxicity -- Management of Toxicity", "content": "General\u00a0measures include airway breathing and circulation To protect against potentially critical arrhythmias, obtain an EKG and quickly initiate cardiac monitoring Protect the patient\u2019s airway, and establish an intravenous line Gastrointestinal Decontamination by large volume gastric lavage followed by activated charcoal Serum alkalinization\u00a0using sodium bicarbonate if EKG exhibits QRS prolongation Dysrhythmias unresponsive to sodium bicarbonate and hyperventilation may respond to phenytoin, lidocaine, or bretylium In patients with CNS depression, early intubation because of the potential for sudden collapse Seizures\u00a0control with benzodiazepines or, if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin) Physostigmine administration should be in close consultation with a poison control center [29]", "contents": "Cyclobenzaprine -- Toxicity -- Management of Toxicity. General\u00a0measures include airway breathing and circulation To protect against potentially critical arrhythmias, obtain an EKG and quickly initiate cardiac monitoring Protect the patient\u2019s airway, and establish an intravenous line Gastrointestinal Decontamination by large volume gastric lavage followed by activated charcoal Serum alkalinization\u00a0using sodium bicarbonate if EKG exhibits QRS prolongation Dysrhythmias unresponsive to sodium bicarbonate and hyperventilation may respond to phenytoin, lidocaine, or bretylium In patients with CNS depression, early intubation because of the potential for sudden collapse Seizures\u00a0control with benzodiazepines or, if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin) Physostigmine administration should be in close consultation with a poison control center [29]"}
{"id": "article-20197_26", "title": "Cyclobenzaprine -- Enhancing Healthcare Team Outcomes", "content": "Cyclobenzaprine is a commonly used medication to manage muscle spasms. While the drug is effective, it has many adverse effects; healthcare providers must understand proper indication, dosage, and toxicity management.\u00a0Ideally, clinicians (MDs, DOs, NPs, PAs) initiate cyclobenzaprine for appropriate indication. Similarly, the dentist may prescribe\u00a0cyclobenzaprine for pain associated with temporomandibular joint disorders. Pharmacists should ensure proper dosing and report to clinicians in case of drug interactions. Nurses should monitor the pain levels and counsel the patient on adherence to therapy.", "contents": "Cyclobenzaprine -- Enhancing Healthcare Team Outcomes. Cyclobenzaprine is a commonly used medication to manage muscle spasms. While the drug is effective, it has many adverse effects; healthcare providers must understand proper indication, dosage, and toxicity management.\u00a0Ideally, clinicians (MDs, DOs, NPs, PAs) initiate cyclobenzaprine for appropriate indication. Similarly, the dentist may prescribe\u00a0cyclobenzaprine for pain associated with temporomandibular joint disorders. Pharmacists should ensure proper dosing and report to clinicians in case of drug interactions. Nurses should monitor the pain levels and counsel the patient on adherence to therapy."}
{"id": "article-20197_27", "title": "Cyclobenzaprine -- Enhancing Healthcare Team Outcomes", "content": "In case of acute cyclobenzaprine overdose, emergency medicine physicians and triage nurses should stabilize the patient. If EKG demonstrates QRS prolongation, the clinician should initiate sodium bicarbonate therapy. In severe overdose, ventricular arrhythmias and seizures may require MICU-level of care under the supervision of a critical care physician. As discussed above, the clinician should consider contacting the poison control center in refractory cases. A psychiatrist consult is required for deliberate poisoning of cyclobenzaprine.", "contents": "Cyclobenzaprine -- Enhancing Healthcare Team Outcomes. In case of acute cyclobenzaprine overdose, emergency medicine physicians and triage nurses should stabilize the patient. If EKG demonstrates QRS prolongation, the clinician should initiate sodium bicarbonate therapy. In severe overdose, ventricular arrhythmias and seizures may require MICU-level of care under the supervision of a critical care physician. As discussed above, the clinician should consider contacting the poison control center in refractory cases. A psychiatrist consult is required for deliberate poisoning of cyclobenzaprine."}
{"id": "article-20197_28", "title": "Cyclobenzaprine -- Enhancing Healthcare Team Outcomes", "content": "As illustrated above, multiple healthcare providers manage the patient on cyclobenzaprine therapy; hence, clinicians (MDs, DOs, NPs, PAs), specialists, physical therapists, pharmacists, nurses, and other healthcare providers should collaborate closely. The clinicians should use the communication tool SBAR (situation, background, assessment, and recommendation) to improve\u00a0patient safety. [30] Excellent\u00a0communication among healthcare providers can improve efficacy and minimizes adverse drug reactions\u00a0related to cyclobenzaprine therapy. An interprofessional team approach translates to\u00a0improved patient outcomes and\u00a0satisfaction. [Level 5]", "contents": "Cyclobenzaprine -- Enhancing Healthcare Team Outcomes. As illustrated above, multiple healthcare providers manage the patient on cyclobenzaprine therapy; hence, clinicians (MDs, DOs, NPs, PAs), specialists, physical therapists, pharmacists, nurses, and other healthcare providers should collaborate closely. The clinicians should use the communication tool SBAR (situation, background, assessment, and recommendation) to improve\u00a0patient safety. [30] Excellent\u00a0communication among healthcare providers can improve efficacy and minimizes adverse drug reactions\u00a0related to cyclobenzaprine therapy. An interprofessional team approach translates to\u00a0improved patient outcomes and\u00a0satisfaction. [Level 5]"}
{"id": "article-20197_29", "title": "Cyclobenzaprine -- Enhancing Healthcare Team Outcomes", "content": "A study on patients suffering from back pain concluded\u00a0that\u00a0clinicians\u00a0could contribute to\u00a0pain management through pharmacotherapy, red flag screening, and reassurance; physical\u00a0therapists could play a crucial role in general exercise and motivation to stay active, and occupation therapists\u00a0can focus on\u00a0disability\u00a0assessment. Thus an interprofessional team involving clinicians, physical therapists, and occupational therapists can significantly improve patient\u00a0care. [31] [Level 5]", "contents": "Cyclobenzaprine -- Enhancing Healthcare Team Outcomes. A study on patients suffering from back pain concluded\u00a0that\u00a0clinicians\u00a0could contribute to\u00a0pain management through pharmacotherapy, red flag screening, and reassurance; physical\u00a0therapists could play a crucial role in general exercise and motivation to stay active, and occupation therapists\u00a0can focus on\u00a0disability\u00a0assessment. Thus an interprofessional team involving clinicians, physical therapists, and occupational therapists can significantly improve patient\u00a0care. [31] [Level 5]"}
{"id": "article-20197_30", "title": "Cyclobenzaprine -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Cyclobenzaprine -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}